Novo Nordisk leaps on new obesity drug data
Novo Nordisk is currently leading the market for incretin therapies with semaglutide-based products Ozempic for type 2 diabetes and Wegovy for obesity, but is coming under competitive pressure from rival therapies from Eli Lilly based on dual GIP/GLP-1 agonist tirzepatide.
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating ...
In a report released today, Richard Vosser from J.P. Morgan maintained a Buy rating on Novo Nordisk (0QIU – Research Report), with a price ...
We recently published a list of 10 Best Stocks to Buy and Hold For 2025. In this article, we are going to take a look at ...
Novo Nordisk's financial strength is evident through its 74% historical average ROIC and 85% gross margin. See why I rate NVO ...
Goldman Sachs analyst James Quigley maintained a Buy rating on Novo Nordisk (0QIU – Research Report) today and set a price target of DKK875.00.
Ironically, Ozempic and Wegovy, as with many of Novo Nordisk’s other products, were created primarily for treating diabetes. The weight-loss factor has become a very profitable and unintended ...
The U.S. government has selected the second batch of drugs up for Medicare price negotiations under the Inflation Reduction ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback